Elucidation of the mechanism of suppressing pulmonary fibrosis by stress proteins and its application to IPF therapy
Project/Area Number |
26460104
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pharmacology in pharmacy
|
Research Institution | Musashino University (2016) Keio University (2014-2015) |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | ストレスタンパク質 / 肺線維症 / スクリーニング / 肺線維化 / 特発性肺線維症 / 既存薬 / 線維症 |
Outline of Final Research Achievements |
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating chronic lung condition with poor prognosis; mean length of survival from time of diagnosis is 2.8-4.2 years.Current agents for treatment of IPF, such as steroids and immunosuppressants, have not been found to improve prognosis.In this study, I identified stress proteins that suppress the onset and progression of IPF, and elucidated the molecular mechanism. I also proposed a new candidate for IPF therapy from a library of medicines already in clinical use. Furthermore, for drug-induced pulmonary fibrosis, we also constructed an animal model focusing on inflammation and examined the effect of stress proteins on the model.
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice.2017
Author(s)
Tanaka K, Niino T, Ishihara T, Sugizaki T, Takafuji A, Takayama T, Kanda Y, Tamura F, Kurotsu S, Kawahara M, Mizushima T.
-
Journal Title
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
[Journal Article] The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice.2015
Author(s)
Tanaka Y, Ishitsuka Y, Hayasaka M, Yamada Y, Miyata K, Endo M, Kondo Y, Moriuchi H, Irikura M, Tanaka K, Mizushima T, Oike Y, Irie T.
-
Journal Title
Pharmacol Res.
Volume: 99
Pages: 52-62
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension.2015
Author(s)
Ishihara, T., Hayashi, E., Yamamoto, S., Kobayashi, C., Tamura, Y., Sawazaki, R., Tamura, F., Tahara, K., Kasahara, T., Ishihara, T., Takenaga, M., Fukuda, K. and Mizushima, T
-
Journal Title
J. Control. Release
Volume: 97
Pages: 97-104
DOI
Related Report
Peer Reviewed
-
[Journal Article] Ameliorative effect of mepenzolate bromide against pulmonary fibrosis.2014
Author(s)
Kurotsu, S., Tanaka, K., Niino, T., Asano, T., Sugizaki, T., Azuma, A., Suzuki, H., Mizushima, T.
-
Journal Title
J. Pharmacol. Exp. Ther.
Volume: 350
Issue: 1
Pages: 79-88
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Synthesis and biological comparison of enantiomers of mepenzolate bromide, a muscarinic receptor antagonist with bronchodilatory and anti-inflammatory activities.2014
Author(s)
Yamashita, Y., Tanaka, K., Asano, T., Yamakawa, N., Kobayashi D., Ishihara, T., Hanaya, K., Shoji, M., Sugai, T., Wada, M., Mashimo, T., Fukunishi, Y. and Mizushima, T.
-
Journal Title
Bioorg. & Medic. Chem.
Volume: 22
Issue: 13
Pages: 3488-3497
DOI
Related Report
Peer Reviewed
-
-
-